Immuno-therapy company Imugene
(ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.
They will start trials with for patients with non-small cell lung cancer.
This the most common type of lung cancer, accounting for around 80 per cent of cases.
Imugene’s MD and CEO, Leslie Chong says the phase 1 trails in 2020 are a an important next step in bringing much needed new therapeutic option to cancer patients.
Shares in Imugene
(ASX:IMU) are trading 2.9 per cent higher at $0.04.
